Author: Govind, R.; Fonseca de Freitas, D.; Pritchard, M.; Khondoker, M.; Teo, J. T.; Stewart, R.; Hayes, R. D.; MacCabe, J. H.
Title: Outcomes of COVID-19 infection in patients treated with Clozapine. Cord-id: st80qouo Document date: 2021_4_19
ID: st80qouo
Snippet: Background Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Aims To investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation and intensive care treatment, and death, among patients taking antipsychotics with schizophrenia-spectrum disorders. Method Using data from South London and Maudsley NHS Foundation Trust (SLAM) clinical r
Document: Background Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Aims To investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation and intensive care treatment, and death, among patients taking antipsychotics with schizophrenia-spectrum disorders. Method Using data from South London and Maudsley NHS Foundation Trust (SLAM) clinical records, via the Clinical Record Interactive Search system, we identified 157 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders, were taking antipsychotics at the time of the COVID-19 pandemic in the UK, and had a laboratory-confirmed COVID-19 infection. The following health outcomes were measured: COVID-related hospitalisation, COVID-related intensive care treatment death. We tested associations between clozapine treatment and each outcome using logistic regression models, adjusting for gender, age, ethnicity, neighbourhood deprivation, obesity, smoking status, diabetes, asthma, bronchitis and hypertension using propensity scores. Results In the 157 individuals who developed COVID while on antipsychotics, there were 44 COVID-related hospitalisations, 13 COVID-related intensive care treatments and 13 deaths of any cause during the follow-up period. In the unadjusted analysis, there was no significant association between clozapine and any of the outcomes and there remained no associations following adjusting for the confounding variables. Conclusions In our sample of patients with COVID-19 and schizophrenia-spectrum disorders, we found no evidence that clozapine treatment puts patients at increased risk of hospitalisation, intensive care treatment or death, compared to any other antipsychotic treatment. However, further research should be considered in larger samples to confirm this.
Search related documents:
Co phrase search for related documents- adjust analysis and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adjust analysis and logistic regression model: 1
- adjust model and logistic regression: 1, 2, 3, 4, 5
- adjust model and logistic regression model: 1, 2, 3, 4
- administrative unit and logistic regression: 1
- administrative unit and logistic regression model: 1
Co phrase search for related documents, hyperlinks ordered by date